CannAssist (OTCQB: CNSC), a biotechnological pharmaceutical and wellness company, believes that its proprietary CiBiDinol technology will be a game-changer. According to a recent article, “the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers.” CBD-based products “reduce inflammation while providing pain relief.” They are also the preferred option because they are “a gentler way to relieve pain and reduce inflammation,” unlike mainstream pharmaceuticals that have dangerous toxicity levels. CiBiDinol’s high efficacy per dose was the subject of “testing conducted via third-party services that confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD.” The article details how CNSC created CiBiDinol and the reason for the efficacy.
To view the full article, visit https://cnw.fm/ZR2t1
About CannAssist International Corporation
CannAssist, the parent company of Xceptor Labs, produces and sells its CiBiDinol technology, formulated using a proprietary process developed by the company’s founder, Mark Palumbo. Research and development aimed at enhancing the bioavailability of oil-soluble molecules resulted in the company’s CiBiDinol technology. CiBiDinol is the driving force behind CannAssist’s Xceptol brand of consumable and topical products. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, Xceptol Pain Cream is a CBD product with industry-defining reliability and compliance. CannAssist believes Xceptol represents the next step for CBD products. CBD is a non-psychoactive compound found in hemp. View the company’s products on RangeMe, an online platform that enables retail buyers to efficiently discover consumer-ready, innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights and services they need. For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://cnw.fm/CNSC
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.